OMEROS CORP

Omeros Corp (OMER) shows zero cyber incidents and zero red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability on those dimensions. However, low signal in a three-month window does not indicate low overall risk; biotech companies face persistent pressures around dilution, financing runway, and clinical development timelines that require deeper historical context. The full $49 Report pulls 12 months of filing data, calculates dilution risk scores, maps financing history and cash burn patterns, and surfaces AI-detected risk signals across executive, operational, and capital structure domains. The full $49 Report adds quantified dilution trajectory, detailed 8-K context, 12-month financing analysis, and forward risk signals.